Aripiprazole (Abilify MyCite)

Combination

WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Schizophrenia (FDA, approved 2017-11-13)

The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2026-04-08. The holder told FDA the product was no longer marketed and asked FDA to withdraw the approval (21 CFR 314.150(c)); FDA states that such a withdrawal is without prejudice to refiling. The trials below are the product's evidence history.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
Phase 2 (3)
Other / comorbidity
NCT02722967 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2016-03 – 2016-09 · Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
What this study did
NCT01981811 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-03 – 2014-12 · Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
What this study did
Phase 4 (5)
Other / comorbidity
NCT03881449 · Durham VA Medical Center
2019-04-04 – 2021-11 · Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
What this study did
NCT03568500 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-05-21 – 2019-09-06 · Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
What this study did
NCT03643159 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-06-28 – 2018-10-17 · Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
What this study did
NCT02404532 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2015-02 – 2015-03 · Device Latency
What this study did
NCT02091882 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-03-21 – 2014-04-18 · Device Latency
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT06372210 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2023-06-26 – 2023-07-19 · Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
What this study did

Competitive landscape

This drug's own stage for Bipolar Disorder: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Aripiprazole (Abilify MyCite): this drugDiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 April 2026WithdrawalFDA withdraws approval of NDA 207202 (Federal Register 2026-04546)
US, FDA · Source ↗